Coverage policy improves access to artificial intelligence-enabled plaque analysis providing insights to help physicians guide treatment decisions for patients with coronary artery disease
MOUNTAIN VIEW, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the global leader in non-invasive artificial intelligence (AI) heart care solutions, today announced HeartFlow Plaque Analysis will be covered by four of seven Medicare Administrative Contractors (MAC) beginning November 24, 2024. This decision will expand patient access to HeartFlow Plaque Analysis, which provides highly accurate plaque quantification and characterization to assess the extent of coronary artery disease (CAD) for personalized treatment. HeartFlow Plaque Analysis is the only FDA-cleared, AI-enabled plaque quantification tool with a reported 95% agreement with the gold standard, IVUS, in a prospective, international trial using blinded core lab adjudication.1 It is proven to change medical management in two-thirds of cases, helping physicians to improve outcomes.2